483 related articles for article (PubMed ID: 31450627)
1. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
Chen SH; Chang JY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450627
[TBL] [Abstract][Full Text] [Related]
2. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
3. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
Kumar A; Kant S; Singh SM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
5. Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy.
Anunobi R; Boone BA; Cheh N; Tang D; Kang R; Loux T; Lotze MT; Zeh HJ
J Surg Res; 2018 Jun; 226():181-191. PubMed ID: 29605400
[TBL] [Abstract][Full Text] [Related]
6. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells.
Hu CF; Huang YY; Wang YJ; Gao FG
Oncol Rep; 2016 Jul; 36(1):455-61. PubMed ID: 27221310
[TBL] [Abstract][Full Text] [Related]
8. Scutellarin synergistically enhances cisplatin effect against ovarian cancer cells through enhancing the ability of cisplatin binding to DNA.
Xie Z; Guo Z; Lei J; Yu J
Eur J Pharmacol; 2019 Feb; 844():9-16. PubMed ID: 30503360
[TBL] [Abstract][Full Text] [Related]
9. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
10. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
Huber RM; Lucas JM; Gomez-Sarosi LA; Coleman I; Zhao S; Coleman R; Nelson PS
Oncotarget; 2015 Feb; 6(4):2134-47. PubMed ID: 25575823
[TBL] [Abstract][Full Text] [Related]
11. Conditioned medium mimicking the tumor microenvironment augments chemotherapeutic resistance via ataxia‑telangiectasia mutated and nuclear factor‑κB pathways in gastric cancer cells.
Zhuang X; Li X; Zhang J; Hu Y; Hu B; Shi Y; Sun Y; Hong G
Oncol Rep; 2018 Oct; 40(4):2334-2342. PubMed ID: 30106453
[TBL] [Abstract][Full Text] [Related]
12. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.
Fu R; Zhao B; Chen M; Fu X; Zhang Q; Cui Y; Hu X; Zhou W
Med Oncol; 2023 Dec; 41(1):9. PubMed ID: 38063931
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment: Sanctuary of the devil.
Hui L; Chen Y
Cancer Lett; 2015 Nov; 368(1):7-13. PubMed ID: 26276713
[TBL] [Abstract][Full Text] [Related]
14. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
15. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
16. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration.
Wangpaichitr M; Theodoropoulos G; Nguyen DJM; Wu C; Spector SA; Feun LG; Savaraj N
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298999
[TBL] [Abstract][Full Text] [Related]
18. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
Smith CIE
Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
20. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
